- Home
- AHCO vs CDTX Comparison
AHCO vs CDTX Comparison
Compare AHCO & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHCO
- CDTX
- Stock Information
- Founded
- AHCO 2012
- CDTX 2012
- Country
- AHCO United States
- CDTX United States
- Employees
- AHCO N/A
- CDTX N/A
- Industry
- AHCO Medical/Nursing Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AHCO Health Care
- CDTX Health Care
- Exchange
- AHCO Nasdaq
- CDTX Nasdaq
- Market Cap
- AHCO 1.2B
- CDTX 1.4B
- IPO Year
- AHCO N/A
- CDTX 2015
- Fundamental
- Price
- AHCO $9.61
- CDTX $66.37
- Analyst Decision
- AHCO Strong Buy
- CDTX Strong Buy
- Analyst Count
- AHCO 5
- CDTX 11
- Target Price
- AHCO $13.40
- CDTX $57.00
- AVG Volume (30 Days)
- AHCO 1.2M
- CDTX 427.5K
- Earning Date
- AHCO 08-05-2025
- CDTX 08-07-2025
- Dividend Yield
- AHCO N/A
- CDTX N/A
- EPS Growth
- AHCO N/A
- CDTX N/A
- EPS
- AHCO 0.54
- CDTX N/A
- Revenue
- AHCO $3,240,757,000.00
- CDTX N/A
- Revenue This Year
- AHCO $1.41
- CDTX N/A
- Revenue Next Year
- AHCO $4.26
- CDTX N/A
- P/E Ratio
- AHCO $17.91
- CDTX N/A
- Revenue Growth
- AHCO N/A
- CDTX N/A
- 52 Week Low
- AHCO $7.11
- CDTX $10.14
- 52 Week High
- AHCO $11.70
- CDTX $69.36
- Technical
- Relative Strength Index (RSI)
- AHCO 54.59
- CDTX 65.51
- Support Level
- AHCO $9.22
- CDTX $59.80
- Resistance Level
- AHCO $9.64
- CDTX $69.36
- Average True Range (ATR)
- AHCO 0.43
- CDTX 3.83
- MACD
- AHCO -0.01
- CDTX -0.38
- Stochastic Oscillator
- AHCO 43.70
- CDTX 76.70
About AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.